Damora Therapeutics, Inc. (DMRA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Damora Therapeutics, Inc. (DMRA) closed at USD 18.43 on 2026-10-14, a change of +157.4 % over the past year, with a market capitalization of USD 1.16B.

Damora Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Damora Therapeutics, Inc. key figures

Previous close

USD 18.43 (2026-10-14)

1-year change

+157.4 %

Market cap

USD 1.16B

Enterprise value

USD 746.41M

P/E ratio (trailing)

-74.96

P/E ratio (forward)

-8.63

EPS (trailing)

-0.25

EPS (forward)

-2.17

PEG ratio

n/a

Price to book

3.00

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.09

Employees

7

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Damora Therapeutics, Inc. and compare it with other stocks.